CN115397392A - 眼用药物组合物 - Google Patents

眼用药物组合物 Download PDF

Info

Publication number
CN115397392A
CN115397392A CN202080094414.9A CN202080094414A CN115397392A CN 115397392 A CN115397392 A CN 115397392A CN 202080094414 A CN202080094414 A CN 202080094414A CN 115397392 A CN115397392 A CN 115397392A
Authority
CN
China
Prior art keywords
composition
ophthalmic
months
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080094414.9A
Other languages
English (en)
Chinese (zh)
Inventor
U·科特雷卡
D·法德科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CN115397392A publication Critical patent/CN115397392A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CN202080094414.9A 2019-12-05 2020-12-04 眼用药物组合物 Pending CN115397392A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944074P 2019-12-05 2019-12-05
US62/944,074 2019-12-05
US202063077196P 2020-09-11 2020-09-11
US63/077,196 2020-09-11
PCT/US2020/063218 WO2021113580A1 (en) 2019-12-05 2020-12-04 Ophthalmic pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CN115397392A true CN115397392A (zh) 2022-11-25

Family

ID=74104179

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080094414.9A Pending CN115397392A (zh) 2019-12-05 2020-12-04 眼用药物组合物

Country Status (14)

Country Link
US (1) US20230026577A1 (https=)
EP (1) EP4069195A1 (https=)
JP (2) JP7833399B2 (https=)
KR (1) KR20220128619A (https=)
CN (1) CN115397392A (https=)
AU (1) AU2020398224B2 (https=)
BR (1) BR112022010871A2 (https=)
CA (1) CA3160484A1 (https=)
CL (1) CL2022001463A1 (https=)
CO (1) CO2022009260A2 (https=)
IL (1) IL293541A (https=)
MX (1) MX2022006776A (https=)
TW (1) TWI845795B (https=)
WO (1) WO2021113580A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300628A (en) * 2020-09-10 2023-04-01 Vanda Pharmaceuticals Inc Methods for the treatment of cyclic diseases or conditions-PDE IV
HU231668B1 (hu) * 2021-12-28 2025-06-28 Semmelweis Egyetem 60% Szemcsepp készítmény
US20250073125A1 (en) * 2023-09-06 2025-03-06 Opus Life Sciences, Llc High ph formulations and kits
WO2025179141A1 (en) 2024-02-22 2025-08-28 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease
KR20260048121A (ko) * 2024-10-02 2026-04-09 주식회사 대웅테라퓨틱스 개선된 안정성 및 투약 편의성을 갖는 레바미피드를 포함하는 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1457256A (zh) * 2000-09-13 2003-11-19 参天制药株式会社 滴眼液
CN106074568A (zh) * 2015-09-02 2016-11-09 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
WO2017083799A1 (en) * 2015-11-13 2017-05-18 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
CN108848668A (zh) * 2015-12-24 2018-11-20 加利福尼亚大学董事会 Cftr调节剂及其使用方法
WO2019040919A1 (en) * 2017-08-24 2019-02-28 The Regents Of The University Of California OCULAR PHARMACEUTICAL COMPOSITIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101537172B (zh) 2008-08-14 2010-06-30 温州医学院 一种含有重组人角质细胞生长因子-2滴眼液及其制备方法
CN101690712B (zh) 2009-08-25 2011-06-15 武汉武药科技有限公司 一种西他沙星滴眼剂及其制备方法
US20110178147A1 (en) 2009-10-20 2011-07-21 Allergan, Inc. Compositions and methods for controlling pupil dilation
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
CN102988280B (zh) 2012-10-08 2014-03-19 新乡医学院 一种加雷沙星滴眼剂
US20180236077A1 (en) 2017-02-21 2018-08-23 Avedro, Inc. Formulations for eye treatments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1457256A (zh) * 2000-09-13 2003-11-19 参天制药株式会社 滴眼液
CN106074568A (zh) * 2015-09-02 2016-11-09 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
WO2017083799A1 (en) * 2015-11-13 2017-05-18 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
CN108848668A (zh) * 2015-12-24 2018-11-20 加利福尼亚大学董事会 Cftr调节剂及其使用方法
WO2019040919A1 (en) * 2017-08-24 2019-02-28 The Regents Of The University Of California OCULAR PHARMACEUTICAL COMPOSITIONS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
顾其胜: "玻璃酸钠生产与临床应用", 31 May 2012, 上海科学技术出版社, pages: 122 - 125 *

Also Published As

Publication number Publication date
KR20220128619A (ko) 2022-09-21
TWI845795B (zh) 2024-06-21
AU2020398224A1 (en) 2022-06-30
AU2020398224B2 (en) 2026-02-19
JP7833399B2 (ja) 2026-03-19
JP2025160247A (ja) 2025-10-22
WO2021113580A1 (en) 2021-06-10
CA3160484A1 (en) 2021-06-10
CO2022009260A2 (es) 2022-09-20
JP2023505255A (ja) 2023-02-08
TW202128178A (zh) 2021-08-01
BR112022010871A2 (pt) 2022-08-23
EP4069195A1 (en) 2022-10-12
MX2022006776A (es) 2022-09-19
IL293541A (en) 2022-08-01
US20230026577A1 (en) 2023-01-26
CL2022001463A1 (es) 2023-02-10

Similar Documents

Publication Publication Date Title
CN115397392A (zh) 眼用药物组合物
EP2707006B1 (en) Stable povidone-iodine compositions with bromfenac
US20100120908A1 (en) Eye drop preparation comprising latanoprost
US8969385B2 (en) Ocular formulations of norketotifen
JP2022116235A (ja) ビタミンａを含有するエマルション点眼液
US9561280B2 (en) Aqueous liquid bromfenac composition having preservative efficacy
JP2010204597A (ja) ソフトコンタクトレンズ用組成物及びソフトコンタクトレンズへの吸着抑制方法
US6849655B2 (en) Aqueous liquid formulations
RU2832581C1 (ru) Офтальмологические фармацевтические композиции
TW201801719A (zh) 眼科用製品及黏度降低抑制方法
US20120135947A1 (en) Oil-in-water emulsion composition containing difluprednate and tobramycin
CN115444849B (zh) 具有改善的防腐效力或光稳定性的眼科药物组合物
BR122024022133A2 (pt) Composições farmacêuticas oftalmológicas e uso das mesmas
JP2011011984A (ja) 仮性近視治療薬
JP2009079032A (ja) 眼科用組成物及びジフェンヒドラミンの安定化方法
HK40082706B (zh) 具有改善的防腐效力或光稳定性的眼科药物组合物
JPWO2001087298A1 (ja) 水性液剤
HK1195002A (en) Stable povidone-iodine compositions with bromfenac
HK1195002B (en) Stable povidone-iodine compositions with bromfenac

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination